# The reading list

> Arizona IV Therapy — reading list — Arizona IV Therapy reading list: NAD+ cell biology, rat IV research, human NADH studies and oral NMN trials, with links to the published papers.

The experimental settings are the useful organising principle: cells, rats, people receiving NADH, and people receiving oral NMN.

## Cell biology and replenishment

The [review of NAD+ in ageing, metabolism and neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/26785480/) and the [review of NAD+ homeostasis in human health and disease](https://pubmed.ncbi.nlm.nih.gov/34041853/) give the replenishment question its biological setting. The [review of NAD+/NADH in cellular function](https://pubmed.ncbi.nlm.nih.gov/18020963/) supplies the paired-form context.

For an actual experiment at the cell boundary, there is the [metabolic-fate study in cultured human skin fibroblasts](https://pubmed.ncbi.nlm.nih.gov/11135366/). The [CD38 deletion study](https://pubmed.ncbi.nlm.nih.gov/27304511/) concerns mice. Their settings remain attached to the findings throughout this notebook.

## IV experiments and human outcomes

The [NAD+ heart-injury experiment](https://pubmed.ncbi.nlm.nih.gov/27648125/) concerns rats. The [small double-blind NADH study](https://pubmed.ncbi.nlm.nih.gov/7887134/) and the [open NADH study alongside conventional therapy](https://pubmed.ncbi.nlm.nih.gov/9013405/) concern Parkinson’s disease.

The [oral NMN muscle-insulin-sensitivity trial](https://pubmed.ncbi.nlm.nih.gov/33888596/) and [multicentre oral NMN trial](https://pubmed.ncbi.nlm.nih.gov/36482258/) provide the specific human outcomes on the trial ledger. The [review of human ageing trials](https://pubmed.ncbi.nlm.nih.gov/41083806/) gives them a wider clinical context. The publication titles follow below.

## References

[1] NAD⁺ in aging, metabolism, and neurodegeneration. https://pubmed.ncbi.nlm.nih.gov/26785480/
[2] Metabolic fate of extracellular NAD in human skin fibroblasts. https://pubmed.ncbi.nlm.nih.gov/11135366/
[3] Exogenous NAD(+) administration significantly protects against myocardial ischemia/reperfusion injury in rat model. https://pubmed.ncbi.nlm.nih.gov/27648125/
[4] Treatment of Parkinson's disease with NADH. https://pubmed.ncbi.nlm.nih.gov/7887134/
[5] Parenteral application of NADH in Parkinson's disease: clinical improvement partially due to stimulation of endogenous levodopa biosynthesis. https://pubmed.ncbi.nlm.nih.gov/9013405/
[6] CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism https://pubmed.ncbi.nlm.nih.gov/27304511/
[7] Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women https://pubmed.ncbi.nlm.nih.gov/33888596/
[8] The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial https://pubmed.ncbi.nlm.nih.gov/36482258/
[9] NAD(+) precursor supplementation in human ageing: clinical evidence and challenges https://pubmed.ncbi.nlm.nih.gov/41083806/
[10] NAD(+) homeostasis in human health and disease. https://pubmed.ncbi.nlm.nih.gov/34041853/
[11] NAD+/NADH and NADP+/NADPH in cellular functions and cell death: regulation and biological consequences. https://pubmed.ncbi.nlm.nih.gov/18020963/

---

Here I follow the NAD+ replenishment story through published research; Arizona IV Therapy offers an editorial notebook, no treatment business and no medical advice.